Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Moderna is all in on mRNA. Each of the more than 40 drugs in ... The company has gone through two chief commercial officers ...

The mRNA treatment landscape is shaping up to be competitive, but the market is also nascent, with the covid pandemic marking the first commercial product from Moderna, the industry leader.

CFO Jamey Mock’s most salient talking points as he seeks to illustrate the advantages of the drugmaker’s mRNA development ... see that Moderna was a research company, with no commercial ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

With only one commercial product – the COVID-19 vaccine – Moderna faces pressure to diversify its pipeline rapidly. As the company invests heavily in expanding its non-COVID mRNA vaccine ...

Moderna MRNA-2.31%decrease; red down pointing triangle secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine as ...

US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna, Inc. (NASDAQ:MRNA) also reported impressive Q3 2024 ... shifts away from pandemic status and becomes an increasingly commercial market (rather than government funded), there is increasing ...

Moderna Inc (NASDAQ:MRNA) stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. On ...